Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15217032 | 1.00 | MEN1 (0.39) | MEN1ALDH1A1MAPTKMT2ASETD7 | |
| SCHEMBL471005 | 0.88 | DRD3 (0.40) | MEN1ALDH1A1MAPTKMT2ASETD7 | |
| SCHEMBL15217026 | 0.88 | DRD3 (0.40) | MEN1ALDH1A1MAPTKMT2ASETD7 | |
| SCHEMBL23867140 | 0.85 | NR1H2 (0.43) | MEN1ALDH1A1MAPTKMT2ASETD7 | |
| SCHEMBL28950964 | 0.85 | NR1H2 (0.43) | MEN1ALDH1A1MAPTKMT2ASETD7 | |
| SCHEMBL28694792 | 0.84 | DRD3 (0.40) | MEN1ALDH1A1MAPTKMT2ASETD7 | |
| SCHEMBL15217027 | 0.84 | DRD3 (0.40) | MEN1ALDH1A1MAPTKMT2ASETD7 | |
| SCHEMBL470960 | 0.84 | DRD3 (0.40) | MEN1ALDH1A1MAPTKMT2ASETD7 | |
| SCHEMBL13568017 | 0.83 | NR1H2 (0.43) | MEN1ALDH1A1MAPTKMT2ASETD7 | |
| SCHEMBL13567959 | 0.83 | NR1H2 (0.43) | MEN1ALDH1A1MAPTKMT2ASETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822448-B2 | Pyrazoloquinoline compound | ASTELLAS PHARMA INC. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225553-A1 | PYRAZOLOQUINOLINE COMPOUND | PDE9A, PDE5A, PDE2A | MEN1 4011/4885ALDH1A1 381/4885MAPT 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.